Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

January 2025

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 January 2025 3
Section H changes to Part II 6
Index 17

Summary of decisions
EFFECTIVE 1 JANUARY 2025

- Amikacin (Biomed) inj 5 mg per ml, 5 ml syringe – price increase
- Amiloride hydrochloride (Biomed) oral liq 1 mg per ml, 25 ml – price increase
- Atracurium besylate (Medsurge) inj 10 mg per ml, 2.5 ml and 5 ml ampoule – new listing and addition of PSS
- Atracurium besylate (Tracrium) inj 10 mg per ml, 2.5 ml and 5 ml ampoule – to be delisted 1 June 2025
- Atropine sulphate (Hikma) inj 600 mcg per ml, 1 ml ampoule – new listing
- Budesonide with glycopyrronium and eformoterol (Breztri Aerosphere) aerosol inhaler budesonide 160 mcg with glycopyrronium 7.2 mcg and formoterol 5 mcg per dose, 120 dose – new listing
- Bupivacaine hydrochloride with fentanyl (Biomed) inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag and inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe – price increase
- Caffeine citrate (Biomed) oral liq 20 mg per ml (caffeine 10 mg per ml), 25 ml and inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule – price increase
- Calcitriol (Calcitriol-AFT) cap 0.25 mcg – new listing
- Cetirizine hydrochloride (Histaclear) oral liq 1 mg per ml, 200 ml – price increase
- Cetomacrogol (Cetomacrogol Cream AFT) crm BP, 100 g – new listing and addition of PSS
- Clomipramine hydrochloride (Clomipramine Teva) cap 10 mg and 25 mg – price increase
- Chlorothiazide (Biomed) oral liq 50 mg per ml, 25 ml – price increase
- Cocaine hydrochloride (Biomed) soln 4%, 2 ml syringe – price increase
- Covid-19 vaccine (Comirnaty Omicron (JN.1)) inj 3 mcg bretovameran per 0.3 ml, 0.48 ml vial; infant vaccine, yellow cap; inj 10 mcg bretovameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap and inj 30 mcg bretovameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap – new listing
- Covid-19 vaccine (Comirnaty Omicron (XBB.1.5)) inj 3 mcg raxtozinameran per 0.2 ml, 0.4 ml vial; infant vaccine, maroon cap; inj 10 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap; inj 30 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap and Inj 30 mcg raxtozinameran per 0.3 ml, 2.25 ml vial; adult vaccine, dark grey cap – to be delisted 1 February 2025
- Cyclopentolate hydrochloride (Cyclogyl) eye drops 1%, 15 ml – price increase
- Cytarabine (Pfizer) inj 20 mg per ml, 5 ml vial – new Pharmacode listing
- Dantrolene (Dantrium) cap 25 mg – new Pharmacode listing

Summary of decisions – effective 1 January 2025 (continued)

- Dantrolene (Dantrium) cap 25 mg – Pharmacode 252409 to be delisted 1 April 2025
- Dexamethasone (Biomed) oral liq 1 mg per ml, 25 ml – price increase
- Durvalumab (Imfinzi) inj 50 mg per ml, 2.4 ml and 10 ml vial – amended restriction criteria
- Econazole nitrate (Pevaryl) crm 1%, 20 g – new listing, addition of PSS and restrictions removed
- Eftrenonacog alfa [recombinant factor IX] (Alprolix) inj 250 iu, 500 iu, 1,000 iu, 2,000 iu, 3,000 iu and 4,000 iu vial – new Pharmacode listing
- Erlotinib (Alchemy) tab 100 mg and 150 mg – amended restriction criteria
- Erythromycin (as ethylsuccinate) (E-Mycin) tab 400 mg and grans for oral liq 200 mg and 400 mg per 5 ml, 100 ml – price increase
- Flecainide acetate (Tambocor German) inj 10 mg per ml, 15 ml ampoule – new listing
- Fluconazole (Fluconazole-Baxter) inj 2 mg per ml, 50 ml and 100 ml vial – price increase
- Folic acid (Biomed) oral liq 50 mcg per ml – price increase
- Gefitinib (Iressa) tab 250 mg – amended restriction criteria
- High protein oral feed 2.4 kcal/ml (e.g. Fortisip Compact Protein) liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle – removal of note and delisted date revoked
- Hydrocortisone acetate (Colifoam) rectal foam 10%, CFC free (14 applications), 15 g – price increase
- Iohexol (Omnipaque) inj 350 mg per ml (iodine equivalent), 75 ml bottle – to be delisted 1 June 2025
- Iron polymaltose (Ferrosig) inj 50 mg per ml, 2 ml ampoule – price increase
- Ketamine (Biomed) inj 1 mg per ml, 100 ml bag and inj 10 mg per ml, 10 ml syringe – price increase
- Lidocaine [lignocaine] hydrochloride (Lidocaine-Baxter) inj 1%, 5 ml ampoule and 20 ml vial and inj 2%, 5 ml ampoule and 20 ml vial – price increase
- Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride (Topicaine) soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe – price increase
- Methylphenidate hydrochloride tab immediate-release 10 mg (Ritalin) and cap modified-release 10 mg, 20 mg, 30 mg and 40 mg (Ritalin LA) – price increase
- Osimertinib (Tagrisso) tab 40 mg and 80 mg – new listing
- Palivizumab (Synagis) inj 100 mg per ml, 1 ml vial – new listing
- Potassium citrate (Biomed) oral liq 3 mmol per ml, 200 ml – price increase

Summary of decisions – effective 1 January 2025 (continued)

- Promethazine hydrochloride (Phenergan Elixir) oral liq 1 mg per ml, 100 ml – new listing
- Risperidone (Risperdal) tab 4 mg – new listing
- Spironolactone (Biomed) oral liq 5 mg per ml, 25 ml – price increase
- Sodium bicarbonate (Biomed) inj 8.4%, 50 ml and 100 ml vial – price increase
- Sodium chloride (Biomed) inj 23.4% (4 mmol/ml), 20 ml ampoule – price increase
- Sodium chloride (Biomed) nebuliser soln 7%, 90 ml bottle, 90 ml – price increase
- Sodium dihydrogen phosphate [sodium acid phosphate] (Biomed) inj 1 mmol per ml, 20 ml ampoule – price increase
- Sodium fusidate [fusidic acid] (Fucithalmic) eye drops 1%, 5 g – new listing
- Solifenacin succinate (Solifenacin succinate Max Health) tab 5 mg and 10 mg – new listing and addition of PSS
- Solifenacin succinate (Solifenacin Viatris) tab 5 mg and 10 mg – to be delisted 1 June 2025
- Sucrose (Biomed) oral liq 25%, 25 ml – price increase
- Trastuzumab deruxtecan (Enhertu) inj 100 mg per ml, 1 ml vial – new listing
- Trastuzumab emtansine (Kadcyla) inj 100 mg and 160 mg vial – amended restriction criteria
- Tropicamide (Mydriacyl) eye drops 0.5% and 1%, 15 ml – price increase

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Section H changes to Part II

Effective 1 January 2025

ALIMENTARY TRACT AND METABOLISM

6	HYDROCORTISONE ACETATE (↑ price)			
	Rectal foam 10%, CFC free (14 applications)	57.09	15 g	Colifoam
23	IRON POLYMALTOSE (↑ price)			
	Inj 50 mg per ml, 2 ml ampoule	37.95	5	Ferrosig
27	CALCITRIOL (new listing)			
	Cap 0.25 mcg	7.89	100	Calcitriol-AFT

BLOOD AND BLOOD FORMING ORGANS

30	FOLIC ACID (↑ price)			
	Oral liq 50 mcg per ml	31.77	25 ml	Biomed
33	EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] (new Pharmacode listing)			
	➔ Inj 250 iu vial	612.50	1	Alprolix
	➔ Inj 500 iu vial	1,225.00	1	Alprolix
	➔ Inj 1,000 iu vial	2,450.00	1	Alprolix
	➔ Inj 2,000 iu vial	4,900.00	1	Alprolix
	➔ Inj 3,000 iu vial	7,350.00	1	Alprolix
	➔ Inj 4,000 iu vial	9,800.00	1	Alprolix
	Note – these are new Pharmacode listings 2696150, 2696169, 2696177, 2696185, 2696193 and 2696207.			
41	SODIUM BICARBONATE (↑ price)			
	Inj 8.4%, 50 ml vial	24.70	1	Biomed
	Inj 8.4%, 100 ml vial	25.31	1	Biomed
41	SODIUM CHLORIDE (↑ price)			
	Inj 23.4% (4 mmol/ml), 20 ml ampoule	40.15	5	Biomed
41	SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE] (↑ price)			
	Inj 1 mmol per ml, 20 ml ampoule	59.10	5	Biomed

CARDIOVASCULAR SYSTEM

45	ATROPINE SULPHATE (new listing)			
	Inj 600 mcg per ml, 1 ml ampoule	16.10	10	Hikma
45	FLECAINIDE ACETATE (new listing)			
	Inj 10 mg per ml, 15 ml ampoule	108.16	5	Tambocor German
49	AMILORIDE HYDROCHLORIDE (↑ price)			
	Oral liq 1 mg per ml	35.40	25 ml	Biomed
49	SPIRONOLACTONE (↑ price)			
	Oral liq 5 mg per ml	35.70	25 ml	Biomed

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 January 2025 (continued)

49 CHLOROTHIAZIDE (↑ price)
Oral liq 50 mg per ml ..... 30.67 — 25 ml — Biomed

DERMATOLOGICALS

66 ECONAZOLE NITRATE (new listing, addition of PSS and restrictions removed)
Crm 1% – ~~Restricted: For continuation only~~
5% DV Jun-25 to 2027 ..... 8.04 — 20 g — **Pevaryl**

67 CETOMACROGOL (new listing and addition of PSS)
Crm BP, 100 g – **5% DV Jun-25 to 2027** ..... 0.99 — 100 g — **Cetomacrogol Cream AFT**

GENITO-URINARY SYSTEM

75 POTASSIUM CITRATE (↑ price)
➔ Oral liq 3 mmol per ml ..... 37.49 — 200 ml — Biomed

76 SOLIFENACIN SUCCINATE (new listing and addition of PSS)
Tab 5 mg – **5% DV Jun-25 to 2027** ..... 1.95 — 30 — **Solifenacin succinate Max Health**
Tab 10 mg – **5% DV Jun-25 to 2027** ..... 3.53 — 30 — **Solifenacin succinate Max Health**
Note – Solifenacin Viatris tab 5 mg and 10 mg to be delisted from 1 June 2025.

HORMONE PREPARATIONS

78 DEXAMETHASONE (↑ price)
Oral liq 1 mg per ml ..... 53.86 — 25 ml — Biomed

INFECTIONS

87 AMIKACIN (↑ price)
➔ Inj 5 mg per ml, 5 ml syringe ..... 22.93 — 1 — Biomed

90 ERYTHROMYCIN (AS ETHYLSUCCINATE) (↑ price)
Tab 400 mg ..... 35.82 — 100 — E-Mycin
Grans for oral liq 200 mg per 5 ml ..... 6.53 — 100 ml — E-Mycin
Grans for oral liq 400 mg per 5 ml ..... 9.41 — 100 ml — E-Mycin

95 FLUCONAZOLE (↑ price)
➔ Inj 2 mg per ml, 50 ml vial ..... 11.20 — 1 — Fluconazole-Baxter
➔ Inj 2 mg per ml, 100 ml vial ..... 5.20 — 1 — Fluconazole-Baxter

MUSCULOSKELETAL SYSTEM

115 ATRACURIUM BESYLATE (new listing and addition of PSS)
Inj 10 mg per ml, 2.5 ml ampoule – **5% DV Jun-25 to 2026** ..... 7.69 — 5 — **Medsurge**
Inj 10 mg per ml, 5 ml ampoule – **5% DV Jun-25 to 2026** ..... 9.86 — 5 — **Medsurge**
Note – Tracrium inj 10 mg per ml, 2.5 ml and 5 ml ampoule to be delisted from 1 June 2025.

115 DANTROLENE (new Pharmacode listing)
Cap 25 mg ..... 112.13 — 100 — Dantrium
Note – this is a new Pharmacode listing 2648946. Pharmacode 252409 to be delisted from 1 April 2025.

		Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 January 2025 (continued)

NERVOUS SYSTEM

119	KETAMINE (↑ price)			
	Inj 1 mg per ml, 100 ml bag	146.00	5	Biomed
	Inj 10 mg per ml, 10 ml syringe	76.00	5	Biomed
120	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL (↑ price)			
	Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag	165.00	5	Biomed
	Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe	57.35	5	Biomed
121	COCAINE HYDROCHLORIDE (↑ price)			
	Soln 4%, 2 ml syringe	30.77	1	Biomed
121	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↑ price)			
	Inj 1%, 5 ml ampoule	15.00	25	Lidocaine-Baxter
	Inj 1%, 20 ml vial	19.50	5	Lidocaine-Baxter
	Inj 2%, 5 ml ampoule	27.50	25	Lidocaine-Baxter
	Inj 2%, 20 ml vial	14.00	5	Lidocaine-Baxter
121	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE (↑ price)			
	Soln 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe	20.50	1	Topicaine
123	SUCROSE (↑ price)			
	Oral liq 25%	14.61	25 ml	Biomed
125	CLOMIPRAMINE HYDROCHLORIDE (↑ price)			
	Cap 10 mg	35.50	28	Clomipramine Teva
	Cap 25 mg	35.50	28	Clomipramine Teva
133	RISPERIDONE (new listing)			
	Tab 4 mg	6.25	60	Risperdal
143	METHYLPHENIDATE HYDROCHLORIDE (↑ price)			
	Tab immediate-release 10 mg	4.00	30	Ritalin
	Cap modified-release 10 mg	19.41	30	Ritalin LA
	Cap modified-release 20 mg	27.72	30	Ritalin LA
	Cap modified-release 30 mg	34.39	30	Ritalin LA
	Cap modified-release 40 mg	38.67	30	Ritalin LA

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

150	CYTARABINE (new Pharmacode listing)			
	Inj 20 mg per ml, 5 ml vial	472.00	5	Pfizer
	Note – this is a new Pharmacode listing 2695758.			

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 January 2025 (continued)

159 ERLOTINIB (amended restriction criteria)

➔Tab 100 mg – **5% DV Oct-24 to 2027** ..... 280.84 30 **Alchemy**

➔Tab 150 mg – **5% DV Oct-24 to 2027** ..... 484.24 30 **Alchemy**

Restricted
Initiation
Re-assessment required after 4 months
All of the following:
1 Patient has locally advanced, or metastatic, unresectable, non-squamous non-small cell lung cancer (NSCLC); and
2 There is documentation confirming that the disease expresses activating mutations of ~~EGFR tyrosine kinase~~ ***EGFR***; and
3 ~~Either~~ **Any of the following**:
  3.1 Patient is treatment naïve; or
  3.2 Patient has received prior treatment in the adjuvant setting and/or while awaiting *EGFR* results; or
  3.3 Both:
    3.3.1 The patient has discontinued **osimertinib or** gefitinib due to intolerance; and
    3.3.2 The cancer did not progress while on **osimertinib or** gefitinib; and
~~4 Erlotinib is to be given for a maximum of 3 months~~

Continuation
Re-assessment required after 6 months
~~1~~ Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed; ~~and~~
~~2 Erlotinib is to be given for a maximum of 3 months~~

~~Continuation – pandemic circumstances~~
~~*Reassessment required after 6 months*~~
~~1 The patient is clinically benefitting from treatment and continued treatment remains appropriate~~
~~2 Erlotinib to be discontinued at progression~~
~~3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on health sector~~

160 GEFITINIB (amended restriction criteria)

➔Tab 250 mg..... 918.00 30 Iressa

Restricted
Initiation
Re-assessment required after 4 months
All of the following:
1 Patient has locally advanced, or metastatic, unresectable, non-squamous non-small cell lung cancer (NSCLC); and
2 ~~Either~~ **Any of the following**:
  2.1 Patient is treatment naïve; or
  2.2 Patient has received prior treatment in the adjuvant setting and/or while awaiting *EGFR* results; or
  2.3 Both:
    2.3.1 The patient has discontinued **osimertinib or** erlotinib due to intolerance; and
    2.3.2 The cancer did not progress while on **osimertinib or** erlotinib; and
3 There is documentation confirming that the disease expresses activating mutations of ~~EGFR tyrosine kinase~~ ***EGFR***; ~~and~~
~~4 Gefitinib is to be given for a maximum of 3 months~~

Continuation
Re-assessment required after 6 months
~~1~~ Radiological assessment (preferably including CT scan) indicates NSCLC has not progressed~~; and~~
~~2 Gefitinib is to be given for a maximum of 3 months~~

~~Continuation – pandemic circumstances)~~
~~*Reassessment required after 6 months*~~
~~1 The patient is clinically benefitting from treatment and continued treatment remains appropriate~~
~~2 Gefitinib to be discontinued at progression~~
~~3 The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on health sector~~

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 January 2025 (continued)

163 OSIMERTINIB (new listing)

➔Tab 40 mg	9,310.00	30	Tagrisso
➔Tab 80 mg	9,310.00	30	Tagrisso

Restricted
Initiation – NSCLC – first line
Re-assessment required after 4 months
All of the following:
1 Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC); and
2 Any of the following:
  2.1 Patient is treatment naïve; or
  2.2 Patient has received prior treatment in the adjuvant setting and/or while awaiting *EGFR* results; or
  2.3 Both:
    2.3.1 The patient has discontinued gefitinib or erlotinib due to intolerance; and
    2.3.2 The cancer did not progress while on gefitinib or erlotinib; and
3 There is documentation confirming that the disease expresses activating mutations of *EGFR*; and
4 Patient has an ECOG performance status 0-3; and
5 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Continuation – NSCLC – first line
Re-assessment required after 6 months
Response to or stable disease with treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

Initiation – NSCLC – second line
Re-assessment required after 4 months
All of the following:
1 Patient has locally advanced or metastatic, incurable, non-squamous non-small cell lung cancer (NSCLC); and
2 Patient has an ECOG performance status 0-3; and
3 The patient must have received previous treatment with erlotinib or gefitinib; and
4 There is documentation confirming that the disease expresses T790M mutation of *EGFR* following progression on or after erlotinib or gefitinib; and
5 The treatment must be given as monotherapy; and
6 Baseline measurement of overall tumour burden is documented clinically and radiologically.

Continuation – NSCLC – second line
Reassessment required after 6 months
Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period.

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 January 2025 (continued)

212 PALIVIZUMAB (new listing)
➔ Inj 100 mg per ml, 1 ml vial ..... 1,700.00 1 Synagis

Restricted
Initiation
Re-assessment required after 6 months
Both:
1 Palivizumab to be administered during the annual RSV season; and
2 Either:
- 2.1 Both:
  - 2.1.1 Infant was born in the last 12 months; and
  - 2.1.2 Infant was born at less than 32 weeks zero days' gestation; or
- 2.2 Both:
  - 2.2.1 Child was born in the last 24 months; and
  - 2.2.2 Any of the following:
    - 2.2.2.1 Child has severe lung, airway, neurological or neuromuscular disease that requires ongoing ventilatory/respiratory support (see Note A) in the community; or
    - 2.2.2.2 Both:
      - 2.2.2.2.1 Child has haemodynamically significant heart disease; and
      - 2.2.2.2.2 Any of the following:
        - 2.2.2.2.2.1 Child has unoperated simple congenital heart disease with significant left to right shunt (see Note B); or
        - 2.2.2.2.2.2 Child has unoperated or surgically palliated complex congenital heart disease; or
        - 2.2.2.2.2.3 Child has severe pulmonary hypertension (see Note C); or
        - 2.2.2.2.2.4 Child has moderate or severe left ventricular (LV) failure (see Note D); or
    - 2.2.2.3 Child has severe combined immune deficiency, confirmed by an immunologist, but has not received a stem cell transplant; or
    - 2.2.2.4 Child has inborn errors of immunity (see Note E) that increase susceptibility to life-threatening viral respiratory infections, confirmed by an immunologist.

Continuation
Re-assessment required after 6 months
All of the following:
1 Palivizumab to be administered during the annual RSV season; and
2 Child was born in the last 24 months; and
3 Any of the following:
- 3.1 Child has severe lung, airway, neurological or neuromuscular disease that requires ongoing ventilatory/respiratory support (see Note A) in the community; or
- 3.2 Both:
  - 3.2.1 Child has haemodynamically significant heart disease; and
  - 3.2.2 Any of the following:
    - 3.2.2.1 Child has unoperated simple congenital heart disease with significant left to right shunt (see Note B); or
    - 3.2.2.2 Child has unoperated or surgically palliated complex congenital heart disease; or
    - 3.2.2.3 Child has severe pulmonary hypertension (see Note C); or
    - 3.2.2.4 Child has moderate or severe left ventricular (LV) failure (see Note D); or
- 3.3 Child has severe combined immune deficiency, confirmed by an immunologist, but has not received a stem cell transplant; or
- 3.4 Child has inborn errors of immunity (see Note E) that increase susceptibility to life-threatening viral respiratory infections, confirmed by an immunologist.

continued...

Changes to Section H Part II – effective 1 January 2025 (continued)

continued...

Notes:

a) Ventilatory/respiratory support includes those on home oxygen, CPAP/VPAP and those with tracheostomies in situ managed at home
b) Child requires/will require heart failure medication, and/or child has significant pulmonary hypertension, and/or infant will require surgical palliation/definitive repair within the next 3 months
c) Mean pulmonary artery pressure more than 25 mmHg
d) LV Ejection Fraction less than 40%
e) Inborn errors of immunity include, but are not limited to, IFNAR deficiencies.

233 TRASTUZUMAB DERUXTECAN (new listing)

➔ Inj 100 mg per ml, 1 ml vial ..... 2,550.00 1 Enhertu

Restricted
Initiation
Re-assessment required after 6 months
All of the following:

1 Patient has metastatic breast cancer expressing HER-2 IHC3+ or ISH+ (including FISH or other current technology); and
2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
3 Either:
  3.1 The patient has received prior therapy for metastatic disease; or
  3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy; and
4 Patient has a good performance status (ECOG 0-1); and
5 Patient has not received prior funded trastuzumab deruxtecan treatment; and
6 Treatment to be discontinued at disease progression.

Continuation
Re-assessment required after 6 months
Both:

1 The cancer has not progressed at any time point during the previous approval period whilst on trastuzumab deruxtecan; and
2 Treatment to be discontinued at disease progression.

Note: Prior or adjuvant therapy includes anthracycline, other chemotherapy, biological drugs, or endocrine therapy.

235 TRASTUZUMAB EMTANSINE (amended restriction criteria – affected criteria shown only)

➔ Inj 100 mg vial..... 2,320.00 1 Kadcyla
➔ Inj 160 mg vial..... 3,712.00 1 Kadcyla

Restricted
Initiation – metastatic breast cancer
Re-assessment required after 6 months
All of the following:

1 Patient has metastatic breast cancer expressing HER-2 IHC3+ or ISH+ (including FISH or other current technology); and
2 Patient has previously received trastuzumab and chemotherapy, separately or in combination; and
3 Either:
  3.1 The patient has received prior therapy for metastatic disease*; or
  3.2 The patient developed disease recurrence during, or within six months of completing adjuvant therapy*; and
4 Patient has a good performance status (ECOG 0-1); and
5 Either
  5.1 Patient does not have symptomatic brain metastases; or
  5.2 Patient has brain metastases and has received prior local CNS therapy; and
~~6 Patient has not received prior funded trastuzumab emtansine; and~~

continued...

Changes to Section H Part II – effective 1 January 2025 (continued)

continued...

6 Either:

6.1 Patient has not received prior funded trastuzumab emtansine or trastuzumab deruxtecan treatment; or

6.2 Both:

6.2.1 Patient has discontinued trastuzumab deruxtecan due to intolerance; and

6.2.2 The cancer did not progress while on trastuzumab deruxtecan; and

7 Treatment to be discontinued at disease progression.

239 DURVALUMAB (amended restriction criteria)

➔Inj 50 mg per ml, 10 ml vial	4,700.00	1	Imfinzi
➔Inj 50 mg per ml, 2.4 ml vial	1,128.00	1	Imfinzi

Restricted

Initiation – non-small cell lung cancer

~~Medical oncologist~~

*Reassessment required after ~~3~~ **4** months*

All of the following:

1 Either:

1.1 Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC); **or** ~~and~~

1.2 Patient has histologically or cytologically documented stage IIb (T1N2a only), locally advanced, unresectable non-small cell lung cancer (NSCLC); and

2 Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy; and

3 Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment; and

4 Patient has an ECOG performance status of 0 or 1; and

5 Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab; and

6 Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition; and

7 Either:

7.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or

7.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and

8 Treatment with durvalumab to cease upon signs of disease progression.

Continuation – non-small cell lung cancer

~~Medical oncologist~~

*Reassessment required after ~~3~~ **4** months*

All of the following:

1 The treatment remains clinically appropriate and the patient is benefitting from treatment; and

2 Either:

2.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or

2.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and

3 Treatment with durvalumab to cease upon signs of disease progression; and

4 Total continuous duration must not exceed 12 months.

RESPIRATORY SYSTEM AND ALLERGIES

253 CETIRIZINE HYDROCHLORIDE (↑ price)

Oral liq 1 mg per ml	3.99	200 ml	Histaclear

253 PROMETHAZINE HYDROCHLORIDE (new listing)

Oral liq 1 mg per ml	10.47	100 ml	Phenergan Elixir

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 January 2025 (continued)

255 BUDESONIDE WITH GLYCOPYRRONIUM AND EFORMOTEROL (new listing)

➔ Aerosol inhaler budesonide 160 mcg with glycopyrronium 7.2 mcg and formoterol 5 mcg per dose .... 79.15 — 120 dose — Breztri Aerosphere

Restricted
Initiation
Both:
1 Patient has a diagnosis of COPD confirmed by spirometry or spirometry has been attempted and technically acceptable results are not possible; and
2 Either:
- 2.1 Both:
  - 2.1.1 Patient is currently receiving an inhaled corticosteroid with long acting beta-2 agonist (ICS/LABA) or a long acting muscarinic antagonist with long acting beta-2 agonist (LAMA/LABA); and
  - 2.1.2 Any of the following:

    Clinical criteria:
    - 2.1.2.1 Patient has a COPD Assessment Test (CAT) score greater than 10; or
    - 2.1.2.2 Patient has had 2 or more exacerbations in the previous 12 months; or
    - 2.1.2.3 Patient has had one exacerbation requiring hospitalisation in the previous 12 months; or
    - 2.1.2.4 Patient has had an eosinophil count greater than or equal to $0.3 \times 10^{\wedge}9$ cells/L in the previous 12 months; or
- 2.2 Patient is currently receiving multiple inhaler triple therapy (inhaled corticosteroid with long-acting muscarinic antagonist and long-acting beta-2 agonist – ICS/LAMA/LABA) and met at least one of the clinical criteria above prior to commencing multiple inhaler therapy.

258 CAFFEINE CITRATE (↑ price)

Oral liq 20 mg per ml (caffeine 10 mg per ml)	16.91	25 ml	Biomed
Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule	69.70	5	Biomed

260 SODIUM CHLORIDE (↑ price)

Nebuliser soln 7%, 90 ml bottle	25.73	90 ml	Biomed

SENSORY ORGANS

261 SODIUM FUSIDATE [FUSIDIC ACID] (new listing)

Eye drops 1%	5.29	5 g	Fucithalmic

266 CYCLOPENTOLATE HYDROCHLORIDE (↑ price)

Eye drops 1%	25.16	15 ml	Cyclogyl

266 TROPICAMIDE (↑ price)

Eye drops 0.5%	20.52	15 ml	Mydriacyl
Eye drops 1%	24.82	15 ml	Mydriacyl

VARIOUS

271 IOHEXOL (delisting)

Inj 350 mg per ml (iodine equivalent), 75 ml bottle	160.00	10	Omnipaque

Note – Omnipaque inj 350 mg per ml (iodine equivalent), 75 ml bottle to be delisted from 1 June 2025.

➔ Restriction
(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 January 2025 (continued)

SPECIAL FOODS

295 HIGH PROTEIN ORAL FEED 2.4 KCAL/ML (removal of note and delisting date revoked)
~~Only to be used for patients currently on or would be using Fortisip or Fortisip Multi Fibre~~
➔ Liquid 14.6 g protein, 25.3 g carbohydrate
and 9.6 g fat per 100 ml, 125 ml bottle *e.g. Fortisip Compact Protein*
Note – Fortisip Compact Protein liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle delisting date revoked.

VACCINES

302 COVID-19 VACCINE (new listing)
➔ Inj 3 mcg bretovameran per 0.3 ml, 0.48 ml vial;
infant vaccine, yellow cap ..... 0.00 10 Comirnaty Omicron (JN.1)

Restricted
Initiation – initial dose
Up to three doses for previously unvaccinated children aged 6 months – 4 years at high risk of severe illness.

➔ Inj 10 mcg bretovameran per 0.3 ml, 0.48 ml vial;
paediatric vaccine, light blue cap ..... 0.00 10 Comirnaty Omicron (JN.1)

Restricted
Initiation – initial dose
Either:
1 One dose for previously unvaccinated children aged 5-11 years old; or
2 Up to three doses for immunocompromised children aged 5-11 years old.

➔ Inj 30 mcg bretovameran per 0.3 ml, 0.48 ml vial;
adult vaccine, light grey cap ..... 0.00 10 Comirnaty Omicron (JN.1)

Restricted
Initiation – initial dose
Any of the following:
1 One dose for previously unvaccinated people aged 12-15 years old; or
2 Up to three doses for immunocompromised people aged 12-15 years old; or
3 Up to two doses for previously unvaccinated people 16-29 years old; or
4 Up to four doses for people aged 16-29 at high risk of severe illness; or
5 One dose for previously unvaccinated people aged 30 and older.

Initiation – additional dose
One additional dose every 6 months for people aged 30 years and over, additional dose is given at least 6 months after last dose.

Continuation – additional dose
One additional dose every 6 months for people aged 30 years and over, additional dose is given at least 6 months after last dose.

	Price (ex man. Excl. GST) $	Per	Brand or Generic Manufacturer

Changes to Section H Part II – effective 1 January 2025 (continued)

302 COVID-19 VACCINE (delisting)

➔Inj 3 mcg raxtozinameran per 0.2 ml, 0.4 ml vial; infant vaccine, maroon cap	0.00	10	Comirnaty Omicron XBB.1.5
➔Inj 10 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap	0.00	10	Comirnaty Omicron (XBB.1.5)
➔Inj 30 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap	0.00	10	Comirnaty Omicron (XBB.1.5)
➔Inj 30 mcg raxtozinameran per 0.3 ml, 2.25 ml vial; adult vaccine, dark grey cap	0.00	10	Comirnaty Omicron (XBB.1.5)

Note – Comirnaty Omicron (XBB.1.5) inj 3 mcg raxtozinameran per 0.2 ml, 0.4 ml vial; infant vaccine, maroon cap; inj 10 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; paediatric vaccine, light blue cap; inj 30 mcg raxtozinameran per 0.3 ml, 0.48 ml vial; adult vaccine, light grey cap and inj 30 mcg raxtozinameran per 0.3 ml, 2.25 ml vial; adult vaccine, dark grey cap to be delisted from 1 February 2025.

Effective 1 December 2024

BLOOD AND BLOOD FORMING ORGANS

39 PEGFILGRASTIM (new listing)

➔Inj 6 mg per 0.6 ml syringe	65.00	1	Ziextenzo AU

NERVOUS SYSTEM

124 OXYCODONE HYDROCHLORIDE (new Pharmacode listing)

Tab immediate-release 5 mg	13.77	100	Oxycodone Amneal
Tab immediate-release 10 mg	18.77	100	Oxycodone Amneal
Tab immediate-release 20 mg	26.77	100	Oxycodone Amneal

Index
Pharmaceuticals and brands

A
Alprolix 6
AMIKACIN 7
AMILORIDE HYDROCHLORIDE 6
ATRACURIUM BESYLATE 7
ATROPINE SULPHATE 6
B
Breztri Aerosphere 14
BUDESONIDE WITH GLYCOPYRRONIUM AND EFORMOTEROL 14
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL 8
C
CAFFEINE CITRATE 14
CALCITRIOL 6
Calcitriol-AFT 6
CETIRIZINE HYDROCHLORIDE 13
CETOMACROGOL 7
Cetomacrogol Cream AFT 7
CHLOROTHIAZIDE 7
CLOMIPRAMINE HYDROCHLORIDE 8
Clomipramine Teva 8
COCAINE HYDROCHLORIDE 8
Colifoam 6
Comirnaty Omicron (JN.1) 15
Comirnaty Omicron (XBB.1.5) 16
Comirnaty Omicron XBB.1.5 16
COVID-19 VACCINE 15, 16
Cyclogyl 14
CYCLOPENTOLATE HYDROCHLORIDE 14
CYTARABINE 8
D
Dantrium 7
DANTROLENE 7
DEXAMETHASONE 7
DURVALUMAB 13
E
ECONAZOLE NITRATE 7
EFTRENONACOG ALFA [RECOMBINANT FACTOR IX] 6
E-Mycin 7
Enhertu 12
ERLOTINIB 9
ERYTHROMYCIN (AS ETHYLSUCCINATE) 7
F
Ferrosig 6
FLECAINIDE ACETATE 6
FLUCONAZOLE 7
Fluconazole-Baxter 7
FOLIC ACID 6
Fortisip Compact Protein 15
Fucithalmic 14
FUSIDIC ACID 14
G
GEFITINIB 9
H
HIGH PROTEIN ORAL FEED 2.4 KCAL/ML 15
Hikma 6
Histaclear 13
HYDROCORTISONE ACETATE 6
I
Imfinzi 13
IOHEXOL 14
Iressa 9
IRON POLYMALTOSE 6
K
Kadcyla 12
KETAMINE 8
L
Lidocaine-Baxter 8
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE 8
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE 8
LIGNOCAINE 8
M
METHYLPHENIDATE HYDROCHLORIDE 8
Mydriacyl 14
O
Omnipaque 14
OSIMERTINIB 10
Oxycodone Amneal 16
OXYCODONE HYDROCHLORIDE 16
P
PALIVIZUMAB 11
PEGFILGRASTIM 16
Pevaryl 7
Phenergan Elixir 13
POTASSIUM CITRATE 7
PROMETHAZINE HYDROCHLORIDE 13
R
RECOMBINANT FACTOR IX 6
Risperdal 8
RISPERIDONE 8
Ritalin 8
Ritalin LA 8
S
SODIUM ACID PHOSPHATE 6
SODIUM BICARBONATE 6
SODIUM CHLORIDE 6, 14
SODIUM DIHYDROGEN PHOSPHATE [SODIUM ACID PHOSPHATE] 6
SODIUM FUSIDATE [FUSIDIC ACID] 14

Index
Pharmaceuticals and brands

SOLIFENACIN SUCCINATE 7
Solifenacin succinate Max Health..... 7
SPIRONOLACTONE 6
SUCROSE 8
Synagis 11
T
Tagrisso 10
Tambocor German 6
Topicaine 8
TRASTUZUMAB DERUXTECAN..... 12
TRASTUZUMAB EMTANSINE..... 12
TROPICAMIDE 14
Z
Ziextenzo AU 16

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government